MBOT Stock
MBOT Stock

Microbot Medical Inc. (MBOT) stock surged 46.40% in the current-market trading session at the price of $7.94 following the strategic cooperation agreement with Stryker Corporation.

MBOT is a pre-clinical medical device corporation that specializes in transformational micro-robotic technologies. The company is centered primarily on artificial and natural lumens within the human body. Its proprietary technology platforms provide the base for the growth of a Multi-Generation Pipeline Portfolio.

Strategic Partnership with Stryker Corporation

On 27th December 2021, MBOT reported signing a strategic collaboration deal with Stryker Corporation, a leading medical technology firm. The company will cooperate with Stryker’s Neurovascular division to integrate neurovascular devices with LIBERTY Robotic System. The partnership intends to design the world’s first reliable robotic procedural kits for specific neurovascular procedures. The company will keep developing the LIBERTY Robotic System for coronary and peripheral procedures as well.

Management Comments

CEO and President of MBOT, Harel Gadot, remarked that they had already guaranteed the sustainable competitive benefits of their LIBERTY Robotic System. The partnership with Stryker will enable them to further grow in the neurovascular field. The similarities in their innovation culture will help them establish a highly differentiated solution to benefit all stakeholders. They will also accelerate their goal of transforming the way robotic surgery had viewed and adopted, Gadot added.

MBOT Secured Third Patent for LIBERTY Robotic System

On 23rd December 2021, MBOT published that it had secured a third patent Notice of Allowance for its LIBERTY Robotic System from the United States Patent and Trademark Office. The company had secured all of the three patents during 2021. Microbot currently has 47 patents issued with 26 pending applications and is submitting more applications to defend its Intellectual Property.

Harel Gadot commented that 2021 had been an incredibly prosperous year for their LIBERTY Robotic System. They are maintaining positive momentum and are optimistic about their prospects. The R&D and IP teams are achieving momentous landmarks that give them the confidence to perform at a high level and manage the operating activities throughout 2022.

LEAVE A REPLY

Please enter your comment!
Please enter your name here